Sintilimab treatment for ureteral carcinoma following bladder cancer leads to leukopenia: a case report.

ABSTRACT: Herein, we present a case report of sintilimab treatment for a patient with ureteral cancer reoccurring after bladder cancer, and exploration of the mechanism of adverse reactions from the aspects of intestinal flora and immunity. We have reported a case of leukopenia in a patient with recurrent ureteral cancer after bladder cancer who was treated with sintilimab. A 52-year-old Chinese man with a history of hypertension and diabetes presented with lower urinary tract symptoms, including painless hematuria, frequent and urgent urination, and micturition without pain. Computed tomography (CT) and 3-dimensional (3D) reconstruction suggested bladder space occupation, bladder cancer was pathologically confirmed after laser resection of the bladder tumor, which then recurred and was subject to r

SUBMITTER: Zhong Z 

PROVIDER: S-EPMC8899141 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature